PCVX

Vaxcyte Inc.

Price

$63.30

return (12m)

99.50%

p/e

-7.84

p/bv

3.03

DIVIDEND YIELD

0.00%

PCVX price

Vaxcyte

If you had invested

exposure

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

Return on Investment PCVX

1 month

3 months

1 year

2 years

5 years

10 years

return

1 month

10.36%

3 months

33.57%

1 year

99.50%

2 years

-19.90%

5 years

195.38%

10 years

0.00%

Asset Comparator

If you had invested

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

Fundamentals PCVX

Valuation

P/E

-7.84

Sector -4.38

Industry -4.38

P/BV

3.03

Sector 2.02

Industry 2.02

P/Revenue (PSR)

Sector -4.40

Industry -4.40

EV/EBITDA

-23.10

Sector -263.09

Industry -263.09

EV/EBIT

-22.65

Sector -702.90

Industry -702.90

P/EBITDA

-7.33

Sector -4.39

Industry -4.39

P/EBIT

-7.16

Sector -4.73

Industry -4.73

P/Total Assets

2.66

Sector 1.49

Industry 1.49

P/Net Current Assets

7.12

Sector -11.70

Industry -11.70

P/Working Capital

6.51

Sector -3.19

Industry -3.19

EPS

-7.39

Sector -2.14

Industry -2.14

BVPS

19.15

Sector 1.85

Industry 1.85

Efficiency

Gross Margin

0.00%

Sector 36.74%

Industry 36.74%

EBITDA Margin

Sector -16,244.81%

Industry -16,244.81%

EBIT Margin

Sector -4,202,541.34%

Industry -4,202,541.34%

Operating Margin

0.00%

Sector -38.22%

Industry -38.22%

Net Profit Margins

0.00%

Sector -39.69%

Industry -39.69%

Asset Turnover

0.00

Sector 0.03

Industry 0.03

Profitability

ROE

-38.59%

Sector -65.14%

Industry -65.14%

ROA

-33.91%

Sector -65.53%

Industry -65.53%

ROIC

-76.78%

Sector -2,103.35%

Industry -2,103.35%

Dividends

Dividend yield

0.00%

Sector -

Industry -

Payout

Sector -

Industry -

Debt

Current Ratio

5.72

Sector 2.90

Industry 2.90

Net Debt / EBITDA

5.01

Sector -6.07

Industry -6.07

Net Debt / EBIT

4.91

Sector -8.26

Industry -8.26

Net Debt / Equity

-0.54

Sector -1.07

Industry -1.07

Gross Debt / Equity

0.00

Sector -0.05

Industry -0.05

Equity/Assets

0.88

Sector 0.41

Industry 0.41

Liabilities/Assets

0.12

Sector 0.39

Industry 0.39

Growth

5Y Revenue CAGR

0.00%

Sector -

Industry -

5Y Earnings CAGR

60.45%

Sector -

Industry -

Fundamentals PCVX

DRAG THE FRAME TO SEE MORE DATA

Assets	Price (US$)	Return 12m	DY	P/E	P/BV	ROE	Net Profit Margins
PCVX Vaxcyte Inc.	$63.30	97.26%	0.00%	-7.84	3.03	-38.59%	0.00%
JNJ Johnson & Johnson	$273.41	58.46%	2.02%	29.66	7.34	24.76%	21.48%
PFE Pfizer Inc.	$28.24	21.45%	6.54%	34.62	1.75	5.07%	6.80%
ABBV AbbVie Inc.	$265.97	33.11%	2.73%	70.02	-74.53	-106.44%	9.81%
NVO Novo Nordisk A/S	$46.48	-9.14%	4.09%	11.13	5.91	53.11%	35.32%
MRK Merck & Co. Inc.	$152.20	87.95%	2.45%	106.68	8.06	7.56%	4.77%
AZN AstraZeneca PLC	$164.95	4.92%	2.07%	22.98	4.77	20.74%	17.02%
BMY Bristol-Myers Squibb Company	$67.61	46.95%	3.93%	14.06	5.85	41.59%	18.87%
ZTS Zoetis Inc.	$76.68	-48.52%	2.77%	11.89	9.88	83.10%	27.49%
REGN Regeneron Pharmaceuticals Inc.	$840.84	43.05%	0.45%	19.09	2.61	13.65%	27.86%
AMGN Amgen Inc.	$442.36	55.11%	2.39%	25.30	18.93	74.80%	22.95%
HALO Halozyme Therapeutics Inc.	$107.62	56.06%	0.00%	27.82	80.17	288.14%	24.86%
MCK McKesson Corporation	$853.71	27.85%	0.38%	22.42	-79.15	-352.96%	1.12%
VRTX Vertex Pharmaceuticals Incorporated	$552.06	41.60%	0.00%	29.26	6.36	21.76%	35.00%
CAH Cardinal Health Inc.	$234.85	58.85%	0.88%	31.61	-19.89	-62.92%	0.67%
HRMY Harmony Biosciences Holdings Inc.	$39.93	9.67%	0.00%	12.18	2.21	18.14%	18.89%
BIIB Biogen Inc.	$221.56	63.02%	0.00%	37.04	1.64	4.43%	8.32%

Stock vs Indice Comparison Tool

If you had invested

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

PCVX Historical Dividends

current DY: 0.00%

5-year average DY: 0.00%

no dividend paid in the period.

ABOUT Vaxcyte

Vaxcyte Inc.

Average Investor10 user rating

4.0 (0 people)

United States

13 years

Founded: 2013

2020

Time since IPO - 6 years

58

Employees

Vaxcyte Inc. (United States) is listed on the Nasdaq and has a market capitalization of $8.34 billion, with shareholders equity totaling $2.76 billion.

The company employs approximately 58 people and operates in the Health Care sector, within the Biotechnology industry.

Over the past 12 months, Vaxcyte Inc. reported $- in revenue, generating net income of $-1.06 billion.

Key financial metrics include a P/E ratio of -7.84, a price-to-book (P/B) ratio of 3.03, and a trailing twelve-month dividend yield of 0.00%.

The company trades under the ticker PCVX.

Market cap

$8.34 billion

Net worth

$2.76 billion

$2,757,940,000.00

Assets

$3.14 billion

$3,138,150,000.00

Total Shares Outstanding

144.00 million

144,000,000

Average Daily Trading Volume

$1.39 million

$1,389,962.00

Sector

Health Care

Industry

Biotechnology

PCVX

PCVX revenue and profits

Financial Results PCVX

DRAG THE FRAME TO SEE MORE DATA

PCVX cash flow

DRAG THE FRAME TO SEE MORE DATA

Discover more assets

BFRA - Biofrontera

$- -0,00% (12M)

P/E

0.00

0.00%

ROE

-893.55%

P/BV

0.00

MCK - McKesson

$853.71 22,07% (12M)

P/E

22.42

0.38%

ROE

-352.96%

P/BV

-79.15

CAH - Cardinal Health

$234.85 55,51% (12M)

P/E

31.61

0.88%

ROE

-62.92%

P/BV

-19.89

JNJ - Johnson & Johnson

$273.41 57,54% (12M)

P/E

29.66

2.02%

ROE

24.76%

P/BV

7.34

ABBV - AbbVie

$265.97 31,23% (12M)

P/E

70.02

2.73%

ROE

-106.44%

P/BV

-74.53

MRK - Merck & Co.

$152.20 86,97% (12M)

P/E

106.68

2.45%

ROE

7.56%

P/BV

8.06

AZN - AstraZeneca

$164.95 5,00% (12M)

P/E

22.98

2.07%

ROE

20.74%

P/BV

4.77

PFE - Pfizer

$28.24 21,16% (12M)

P/E

34.62

6.54%

ROE

5.07%

P/BV

1.75

BFRA - Biofrontera

$- -0,00% (12 M)

P/L

0.00

0.00%

ROE

-893.55%

P/VP

0.00

MCK - McKesson

$853.71 22,07% (12 M)

P/L

22.42

0.38%

ROE

-352.96%

P/VP

-79.15

CAH - Cardinal Health

$234.85 55,51% (12 M)

P/L

31.61

0.88%

ROE

-62.92%

P/VP

-19.89

JNJ - Johnson & Johnson

$273.41 57,54% (12 M)

P/L

29.66

2.02%

ROE

24.76%

P/VP

7.34

ABBV - AbbVie

$265.97 31,23% (12 M)

P/L

70.02

2.73%

ROE

-106.44%

P/VP

-74.53

MRK - Merck & Co.

$152.20 86,97% (12 M)

P/L

106.68

2.45%

ROE

7.56%

P/VP

8.06

AZN - AstraZeneca

$164.95 5,00% (12 M)

P/L

22.98

2.07%

ROE

20.74%

P/VP

4.77

PFE - Pfizer

$28.24 21,16% (12 M)

P/L

34.62

6.54%

ROE

5.07%

P/VP

1.75

Frequently Asked Questions

What is the price of Vaxcyte (PCVX) today?

A cotação de Vaxcyte (PCVX) hoje está em US$ 63.30, com uma variação de 99.5% em relação ao último ano. A cotação de Vaxcyte (PCVX) iniciou o ano negociando na casa dos US$ 46.14 e hoje está em US$ 63.30. Acompanhe o gráfico de cotação em tempo real, a cotação histórica de Vaxcyte (PCVX) e dados de ações do Ibovespa e mercados internacionais.

Quando Vaxcyte (PCVX) paga dividendos?

Vaxcyte (PCVX) não distribuiu dividendos no último ano.

Is Vaxcyte (PCVX) a good investment?

Atualmente, Vaxcyte (PCVX) está cotada a US$ 63.30, com um P/L de -7.84, representando um desvio de -1,589% em relação ao seu P/L médio histórico. No último ano, a ação apresentou uma variação de 99.5 em sua cotação e distribuiu US$ 0.00 em dividendos, resultando em um Dividend Yield de 0.00%. O retorno total do acionista foi de 99.50%.

Investors should keep in mind that past performance does not guarantee future results. This information is provided for educational purposes only and should not be considered investment advice.

How can I buy Vaxcyte (PCVX) stock?

Investir em ações de Vaxcyte (PCVX) pode ser feito de duas formas: comprando a stock uma empresa estrangeira e é atrelado ao dólar.

How much would 100 shares of Vaxcyte (PCVX) yield today?

A rentabilidade de Vaxcyte (PCVX) foi de 10.36% no último mês, 99.50% no último ano e 195.38% nos últimos 5 anos (já considerando valorização e dividendos).

Nos últimos 12 meses, a empresa pagou um total de US$ 0.00 em dividendos, um Dividend Yield de 0.00%.

Se você quisesse comprar 100 ações de Vaxcyte (PCVX) hoje, o investimento total seria de US$ 6,330.00, com base na cotação atual de US$ 63.30.

Based on historical performance, the investment would have grown to approximately:

Em 1 ano: US$ 12,628.35
Em 5 anos: US$ 18,697.55
Em 10 anos: US$ 6,330.00

Past performance does not guarantee future results. This content is for informational purposes only and should not be considered investment advice.

PCVX

Vaxcyte Inc.

Price

return (12m)

p/e

p/bv

DIVIDEND YIELD

Return on Investment PCVX

Valuation

Efficiency

Profitability

Dividends

Debt

Growth

COMPARING PCVX WITH OTHER STOCK

current DY: 0.00%

5-year average DY: 0.00%

ABOUT Vaxcyte

Vaxcyte Inc.

United States

13 years

2020

58

PROFIT X PRICE PCVX

Financial Results PCVX

PCVX cash flow

Asset, Revenue and Profit Growth - PCVX

PCVX balance sheet

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

PFE - Pfizer

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

PFE - Pfizer

Frequently Asked Questions